We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01447927
Recruitment Status : Completed
First Posted : October 6, 2011
Results First Posted : July 21, 2014
Last Update Posted : July 21, 2014
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This randomized phase II trial studies how well metformin hydrochloride works in preventing esophageal cancer in patients with Barrett esophagus. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of metformin hydrochloride may keep esophageal cancer from forming.

Condition or disease Intervention/treatment Phase
Barrett Esophagus Esophageal Cancer Drug: metformin hydrochloride Other: placebo Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 93 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Randomized Double Blind Placebo Controlled Trial of Barrett's Esophagus Chemoprevention With Metformin
Study Start Date : June 2012
Actual Primary Completion Date : May 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm I
Patients receive extended-release metformin hydrochloride PO QD on week 1, and BID on weeks 2-12 (QAM QPM on week 3) in the absence of unacceptable toxicity or disease progression.
Drug: metformin hydrochloride
Given PO QD and BID
Other Name: Glucophage

Placebo Comparator: Arm II
Patients receive extended-release placebo PO QD on week 1and BID on weeks 2-12 (QAM and QPM on week 3) in the absence of unacceptable toxicity or disease progression.
Other: placebo
Given PO QD and BID
Other Name: PLCB

Primary Outcome Measures :
  1. Percent Change in Median pS6K1 Immunostaining Among Participants With Barrett Esophagus [ Time Frame: Baseline to 3 months ]
    The percent change in pS6K1 was calculated as month 3 pS6k1 values minus baseline pS6k1 values, then divide by baseline pS6k1 values and multiply by 100.

Secondary Outcome Measures :
  1. Overall Adverse Event Rates [ Time Frame: Up to 30 days ]

    Number of patients that experienced adverse events (grade 1 or above) as measured by NCI CTCAE (Common Terminology Criteria for Adverse Events) v. 4.0.

    The data reported in the table include only the commonly occurring adverse events (3 or more events).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed diagnosis of Barrett esophagus, with no dysplasia, indeterminate for dysplasia, or low-grade dysplasia as defined by the presence of specialized columnar epithelium on histology and >= 2 cm of involvement on endoscopy
  • Adequate Barrett mucosa, which is defined as >= 1 out of 4 research samples (i.e., >= 25%) with >= 50% intestinal metaplasia in biopsies required to satisfy the endpoints of the study
  • No history of esophageal carcinoma or other cancer(s) (except for non-melanoma skin cancers)
  • No erosive esophagitis or ulcerative esophagitis, unless treatment with a proton pump inhibitor (PPI) results in healed erosions or ulcers prior to entry endoscopy
  • No history of high-grade dysplasia or cancer (confirmed locally by esophagogastroduodenoscopy [EGD] and Pathology reports)

    • No ulcer, plaque, nodule, stricture, or other luminal irregularity within the Barrett segment, unless clinical biopsy produces no evidence of high-grade dysplasia or cancer
  • ECOG performance status =< 1
  • Hemoglobin >= 10 g/dL
  • Leukocytes >= 3,000/mL (>= 2,500/mL for African-American participants)
  • Absolute neutrophil count >= 1,500/mL (>= 1,000/mL for African-American participants)
  • Platelets >= 100,000/mL
  • Total bilirubin =< institutional upper limit of normal (ULN)
  • AST (SGOT) and ALT (SGPT) =< 1.5 times institutional ULN
  • Creatinine =< institutional ULN
  • Willingness to provide tissue samples for research purposes
  • No contraindication to esophagogastroduodenoscopy (EGD)
  • Willingness, for both men and women, to use adequate contraception (hormonal or barrier method of birth control; surgical intervention; abstinence) prior to study entry and for the duration of study participation
  • A negative (serum or urine) pregnancy test done =< 7 days prior to Pre-Registration, for women of childbearing potential only
  • No pregnant or nursing women
  • No participants with diabetes mellitus
  • No history of vitamin B12 deficiency or megaloblastic anemia
  • No history of lactic acidosis
  • No diseases associated with weight loss: anorexia, bulimia, or nausea
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin
  • No participants with HIV, cirrhosis of any cause, NASH (non-alcoholic steatohepatitis), or hepatitis (auto-immune or infectious)

    • For participants diagnosed with any other hepatic impairment, consult with protocol principal investigator (PI)
  • No metabolic acidosis, acute or chronic, including ketoacidosis
  • No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; this includes significant medical conditions including renal failure, hepatic failure, sepsis, and hypoxia
  • No genetics disorders such as family history of hereditary gastrointestinal polyp disorder (e.g., familial adenomatous polyposis [FAP], hereditary non-polyposis colorectal cancer [HNPCC], Peutz-Jegher disease)
  • No chronic alcohol use or a history of alcohol abuse (defined as ingestion of >= 3 drinks per day)
  • No kidney disease or renal insufficiency (defined as serum creatinine outside the normal institutional limits)
  • Currently on a proton pump inhibitor (PPI) >= 4 weeks (any PPI taken at least once daily is acceptable)
  • No medication(s) for weight loss ≤ 2 months prior to Pre-Registration
  • No treatment with medications that may increase metformin hydrochloride levels: cationic drugs, e.g., digoxin, amiloride, procainamide, ranitidine, trimethoprim, quinidine, quinine, vancomycin, triamterene, and morphine
  • No treatment with other oral hypoglycemic agents
  • No participant use of metformin, cimetidine (Tagamet), furosemide (Lasix), or nifedipine (Cardizem), or any other drug contraindicated for use with metformin
  • No receipt of any other investigational agents =< 3 months prior to Pre-Registration, except innocuous agents with no known interaction with the study agent (e.g., standard dose multivitamins or topical agents for limited skin conditions), at the discretion of the Protocol Lead Investigator at each Participating Site
  • No participants who have undergone ablation or other local therapies (e.g., percutaneous dilatational tracheostomy [PDT], cryotherapy, radiofrequency, argon plasma coagulation [APC], or multipolar electrocoagulation [MPEC])

    • Patients treated with endoscopic mucosal resection [EMR] allowed
  • No participants anticipating elective surgery during the study period
  • No participants planning to undergo elective radiologic studies involving intravascular administration of iodinated contrast materials

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01447927

Layout table for location information
United States, Illinois
Hines Veterans Administration Hospital
Hines, Illinois, United States, 60141
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Ohio
Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106
United States, Pennsylvania
University of Pittsburgh Medical Center - Shadyside Hospital
Pittsburgh, Pennsylvania, United States, 15232
Canada, Ontario
University of Toronto
Toronto, Ontario, Canada, M5S 1A1
Puerto Rico
University of Puerto Rico
San Juan, Puerto Rico, 00936
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Amitabh Chak Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01447927    
Other Study ID Numbers: NCI-2011-03451
First Posted: October 6, 2011    Key Record Dates
Results First Posted: July 21, 2014
Last Update Posted: July 21, 2014
Last Verified: June 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Esophageal Neoplasms
Barrett Esophagus
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Precancerous Conditions
Hypoglycemic Agents
Physiological Effects of Drugs